Biogen's Early-Stage Alzheimer's Data Continues to Impress Post author:Sam Post published:November 1, 2017 Post category:BioPharma ALZ’s researchers continue to see hope in Biogen’s aducanumab. Source: BioSpace You Might Also Like San Diego-based Biotech Expands for Future Growth and Top Talent August 6, 2017 Novartis AG Lays Out R&D Game Plan at Meet and Greet With 30 Execs in Boston May 31, 2017 Genentech Gets a Phase III Win With Hemophila A Drug Hemlibra November 19, 2017
